JP2021036882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021036882A5 JP2021036882A5 JP2020185772A JP2020185772A JP2021036882A5 JP 2021036882 A5 JP2021036882 A5 JP 2021036882A5 JP 2020185772 A JP2020185772 A JP 2020185772A JP 2020185772 A JP2020185772 A JP 2020185772A JP 2021036882 A5 JP2021036882 A5 JP 2021036882A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- amino acid
- ctl epitopes
- ctl
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012904604A AU2012904604A0 (en) | 2012-10-19 | Improved human cytomegalovirus immunotherapy protein | |
| AU2012904604 | 2012-10-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018207238A Division JP6846396B2 (ja) | 2012-10-19 | 2018-11-02 | 改良されたヒトヘルペスウイルス免疫療法用タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021036882A JP2021036882A (ja) | 2021-03-11 |
| JP2021036882A5 true JP2021036882A5 (https=) | 2021-07-26 |
| JP7110302B2 JP7110302B2 (ja) | 2022-08-01 |
Family
ID=50487350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537084A Pending JP2015533366A (ja) | 2012-10-19 | 2013-10-21 | 改良されたヒトヘルペスウイルス免疫療法 |
| JP2018010690A Pending JP2018075034A (ja) | 2012-10-19 | 2018-01-25 | 改良されたヒトヘルペスウイルス免疫療法 |
| JP2018207238A Active JP6846396B2 (ja) | 2012-10-19 | 2018-11-02 | 改良されたヒトヘルペスウイルス免疫療法用タンパク質 |
| JP2020185772A Active JP7110302B2 (ja) | 2012-10-19 | 2020-11-06 | 改良されたヒトヘルペスウイルス免疫療法用タンパク質 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537084A Pending JP2015533366A (ja) | 2012-10-19 | 2013-10-21 | 改良されたヒトヘルペスウイルス免疫療法 |
| JP2018010690A Pending JP2018075034A (ja) | 2012-10-19 | 2018-01-25 | 改良されたヒトヘルペスウイルス免疫療法 |
| JP2018207238A Active JP6846396B2 (ja) | 2012-10-19 | 2018-11-02 | 改良されたヒトヘルペスウイルス免疫療法用タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9901632B2 (https=) |
| EP (3) | EP2909238A4 (https=) |
| JP (4) | JP2015533366A (https=) |
| CN (2) | CN104918960B (https=) |
| AU (2) | AU2013332272B2 (https=) |
| CA (1) | CA2889064A1 (https=) |
| WO (1) | WO2014059489A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2909238A4 (en) | 2012-10-19 | 2016-11-30 | Queensland Inst Med Res | IMPROVED IMMUNOTHERAPY AGAINST HUMAN HERPESVIRUS |
| NZ736675A (en) * | 2015-05-12 | 2023-03-31 | Memorial Sloan Kettering Cancer Center | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy |
| CN105030047A (zh) * | 2015-08-31 | 2015-11-11 | 捷赛厨电（北京）科技有限公司 | 可控制油烟的炒锅 |
| CN110234358A (zh) * | 2016-07-18 | 2019-09-13 | 昆士兰医学研究所理事会 | 多病毒特异性的t细胞免疫疗法 |
| BR112020012361A2 (pt) * | 2017-12-20 | 2020-11-24 | Glaxosmithkline Biologicals S.A. | constructos de antígeno do vírus epstein-barr |
| AU2019268545A1 (en) * | 2018-05-18 | 2020-12-10 | The Council Of The Queensland Institute Of Medical Research | Adoptive T-cell therapy for CMV infection and CMV-associated diseases |
| US20210301255A1 (en) | 2018-09-10 | 2021-09-30 | Atara Biotherapeutics, Inc. | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto |
| US11810904B2 (en) | 2020-02-24 | 2023-11-07 | PlayNitride Display Co., Ltd. | Micro light emitting diode structure and manufacturing method thereof and micro light emitting diode device |
| CN111394376B (zh) * | 2020-03-30 | 2023-04-28 | 济宁医学院 | 一种融合基因bfna、重组腺病毒及其制备方法和应用 |
| JP2023526766A (ja) * | 2020-04-28 | 2023-06-23 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | ヒトサイトメガロウイルスポリエピトープワクチン組成物 |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| AU2021356478A1 (en) * | 2020-10-07 | 2023-06-01 | The Council Of The Queensland Institute Of Medical Research | Herpesvirus polyepitope vaccines |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM446594A0 (en) | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
| US6703024B2 (en) * | 1996-05-24 | 2004-03-09 | The Council Of The Queensland Institute Of Medical Research | EBV CTL epitopes |
| AUPO007396A0 (en) | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| US7005131B1 (en) * | 1999-08-13 | 2006-02-28 | The Rockefeller University | Protective antigen of Epstein Barr Virus |
| EP1242108B1 (en) | 1999-12-28 | 2007-07-11 | Pharmexa Inc. | Optimized minigenes and peptides encoded thereby |
| AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| AU2002950183A0 (en) * | 2002-07-12 | 2002-09-12 | The Council Of The Queensland Institute Of Medical Research | Expression of hydrophobic proteins |
| CA2500955A1 (en) | 2002-10-03 | 2004-04-15 | Genencor International, Inc. | Optimized multi-epitope constructs and uses thereof |
| US20070048329A1 (en) | 2002-11-07 | 2007-03-01 | Rajiv Khanna | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| DE602004021260D1 (de) * | 2003-07-11 | 2009-07-09 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
| US7976845B2 (en) * | 2004-11-29 | 2011-07-12 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
| CA2611721C (en) | 2005-06-30 | 2014-04-22 | Eisai Co., Ltd. | Compounds for preparing immunological adjuvant |
| EP2313503A4 (en) * | 2008-08-01 | 2014-01-08 | Merck Sharp & Dohme | Variant HCMV-PP65, IE1 and IE2 polynucleotides, and uses thereof |
| WO2010114628A2 (en) * | 2009-04-03 | 2010-10-07 | Duke University | Formulation for inducing broadly reactive neutralizing anti-hiv antibodies |
| US20120052088A1 (en) * | 2009-04-30 | 2012-03-01 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| JP6294076B2 (ja) * | 2011-01-06 | 2018-03-14 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | 多量体ペプチド |
| EP2909238A4 (en) | 2012-10-19 | 2016-11-30 | Queensland Inst Med Res | IMPROVED IMMUNOTHERAPY AGAINST HUMAN HERPESVIRUS |
-
2013
- 2013-10-21 EP EP13847496.0A patent/EP2909238A4/en not_active Withdrawn
- 2013-10-21 CN CN201380065495.XA patent/CN104918960B/zh active Active
- 2013-10-21 WO PCT/AU2013/001216 patent/WO2014059489A1/en not_active Ceased
- 2013-10-21 EP EP18207655.4A patent/EP3466980A3/en not_active Withdrawn
- 2013-10-21 CN CN202410527083.3A patent/CN118359733A/zh active Pending
- 2013-10-21 US US14/436,239 patent/US9901632B2/en active Active
- 2013-10-21 AU AU2013332272A patent/AU2013332272B2/en active Active
- 2013-10-21 JP JP2015537084A patent/JP2015533366A/ja active Pending
- 2013-10-21 CA CA2889064A patent/CA2889064A1/en active Pending
- 2013-10-21 EP EP21157985.9A patent/EP3872097A1/en active Pending
-
2018
- 2018-01-02 US US15/860,145 patent/US11065329B2/en active Active
- 2018-01-25 JP JP2018010690A patent/JP2018075034A/ja active Pending
- 2018-11-02 JP JP2018207238A patent/JP6846396B2/ja active Active
- 2018-12-06 AU AU2018274961A patent/AU2018274961A1/en not_active Abandoned
-
2020
- 2020-11-06 JP JP2020185772A patent/JP7110302B2/ja active Active
-
2021
- 2021-04-09 US US17/226,929 patent/US11896665B2/en active Active
-
2023
- 2023-12-21 US US18/393,160 patent/US20240156953A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021036882A5 (https=) | ||
| Khanna et al. | Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation | |
| Ruiss et al. | A virus-like particle-based Epstein-Barr virus vaccine | |
| Khanna et al. | Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. | |
| Jonjić et al. | A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection | |
| CN100526331C (zh) | 来自ebv的ctl表位 | |
| Yang et al. | Virus-induced polyclonal cytotoxic T lymphocyte stimulation. | |
| Gonczol et al. | Development of a cytomegalovirus vaccine: lessons from recent clinical trials | |
| Moss et al. | The immunology of Epstein–Barr virus infection | |
| Zarling et al. | Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus | |
| Dasari et al. | Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases | |
| JP2019511921A5 (https=) | ||
| US5869453A (en) | Cytotoxic T-cell epitopes | |
| Mühe et al. | Non-human primate lymphocryptoviruses: past, present, and future | |
| Wang et al. | The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus | |
| Mo et al. | A heat shock protein based polyvalent vaccine targeting HSV-2: CD4+ and CD8+ cellular immunity and protective efficacy | |
| Torres et al. | DNA immunization: effect of secretion of DNA-expressed hemagglutinins on antibody responses | |
| Lockey et al. | Epstein-Barr virus vaccine development: a lytic and latent protein cocktail | |
| Khanna et al. | Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells | |
| CN115894708B (zh) | 一种人巨细胞病毒抗原表位嵌合肽及其应用 | |
| WO2025082236A1 (zh) | 识别ebv抗原的t细胞受体及其应用 | |
| Carter et al. | Intratypic and intertypic specificity of lymphocytes involved in the recognition of herpes simplex virus glycoproteins | |
| Grose | Glycoproteins of varicella-zoster virus and their herpes simplex virus homologs | |
| Iii et al. | Functional T cell recognition of synthetic peptides corresponding to continuous antibody epitopes of herpes simplex virus type 1 glycoprotein D | |
| Bharadwaj et al. | Epstein-Barr virus vaccine: a cytotoxic T-cell-based approach |